Clinical Trial Update: A Study To Evaluate CKD-701 and Lucentis® in Patients With Neovascular(Wet) Age Related Macular Degeneration [Phase 3]

View source ↗

Summary

APhase 3 trial evaluating CKD-701 and Lucentis in neovascular (wet) age-related macular degeneration has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neovascular Age-related Macular Degeneration
• Wet Age-related Macular Degeneration

Drugs mentioned

• CKD-701
• Lucentis (ranibizumab)

Snippet

Sponsor: Chong Kun Dang Pharmaceutical | Conditions: Neovascular(Wet) Age Related Macular Degeneration | Phase 3 | Status: COMPLETED